IMS Health Acquires Privacy Analytics, Advancing Real-World Evidence Technology to Drive R&D and Commercial Performance
25 Mayo 2016 - 8:00AM
Business Wire
IMS Health (NYSE:IMS) has acquired Privacy Analytics
Incorporated, a leader in technology solutions for de-identifying
and anonymizing healthcare information, to extend its robust
Real-World Evidence (RWE) capabilities. Affirming IMS Health’s
long-standing practices for safeguarding patient privacy, the
acquisition advances the company’s ability to help life sciences
clients drive R&D and commercial performance and demonstrate
treatment value in real-world settings. It also reinforces IMS
Health’s role as a partner of choice for health systems, payers,
providers and researchers as they seek new insights from healthcare
data—with strong support for responsible privacy management.
Canada-based Privacy Analytics offers an innovative suite of
data governance software and advisory services that enable
stakeholders to optimize benefits of the growing volume and
availability of new, complex datasets while protecting patient
privacy. Solutions include scalable tools for de-identifying and
anonymizing structured and unstructured patient-level data.
Combining Privacy Analytics’ proprietary capabilities—a proven
standard for safeguarding personal health information and ensuring
privacy compliance—with IMS Health’s mission-critical anonymous
information, data management capabilities, and scientific and
commercial expertise will enhance the usability of real-world data
globally.
“Our team of healthcare data privacy experts has pioneered the
methodologies, software and services that enable responsible use of
complex health information,” said Khaled El Emam, founder and CEO,
Privacy Analytics. “We are excited to join IMS Health, which offers
us a global platform and leading-edge technologies that bring our
privacy compliance innovations to a broader client base across life
sciences and healthcare.”
Privacy Analytics’ capabilities will be used across IMS Health
to develop innovative approaches and enhance existing methods for
ensuring the responsible use of anonymous healthcare information.
In addition, the solutions will continue to be offered to Privacy
Analytics and IMS Health clients as an independent suite of
products.
“This acquisition strengthens our role as a leading patient
privacy and data protection advocate while increasing the value
clients across healthcare can realize from real-world evidence,”
said Jon Resnick, vice president and general manager, RWE
Solutions, IMS Health. “Applying this proven standard globally, we
can unleash the full potential of end-to-end RWE insights, from
clinical trials through commercial execution. Privacy Analytics
extends our ability to connect healthcare stakeholders—ultimately
helping to improve the health of patients and the care delivery
systems serving them.”
About IMS Health
IMS Health is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our
7,000 services experts connect configurable SaaS applications to
15+ petabytes of complex healthcare data in the IMS One™ cloud
platform, delivering unique insights into diseases, treatments,
costs and outcomes. The company’s 15,000 employees blend global
consistency and local market knowledge across 100 countries to help
clients run their operations more efficiently. Customers include
pharmaceutical, consumer health and medical device manufacturers
and distributors, providers, payers, government agencies,
policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS
Health uses anonymous healthcare data to deliver critical,
real-world disease and treatment insights. These insights help
biotech and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders to
identify unmet treatment needs and understand the effectiveness and
value of pharmaceutical products in improving overall health
outcomes. Additional information is available at
www.imshealth.com.
About Privacy Analytics
Privacy Analytics enables healthcare organizations to quickly
and easily apply a risk-based responsible de-identification
methodology that ensures individual privacy and legal compliance.
Privacy Analytics is the only company to offer expert training,
software, peer-reviewed methodology and valued-added services that
protect the privacy of individuals while enabling organizations to
share data for secondary purposes. Privacy Analytics’ customers
represent half of Fortune 50 healthcare companies. Privacy
Analytics’ software is compliant with regulations and globally
accepted standards and guidelines, including those from the
Institute of Medicine (IOM), Health Information Trust Alliance
(HITRUST), PhUSE, the Council of Canadian Academies, as well as
HIPAA and the EU Data Protection Directive 95/46/EC. Additional
information is available at www.privacy-analytics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160525005195/en/
IMS HealthMedia RelationsTor Constantino,
+1-484-567-6732tconstantino@us.imshealth.com
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
